INR 18.99
(-0.05%)
Breakdown | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | - | - | - | 15.58 Million |
Cost of Revenue | - | - | 671 Thousand | 11.23 Million |
Gross Profit | - | - | -671 Thousand | 4.34 Million |
Operating Expenses | 5.85 Million | 4.09 Million | 5.13 Million | 13.79 Million |
Selling, General and Administrative Expenses | 366 Thousand | 399 Thousand | 380 Thousand | 438 Thousand |
Research and Development Expenses | - | - | - | - |
Other Expenses | 4.2 Million | 416 Thousand | 1.03 Million | 2.91 Million |
Cost and Expenses | 5.85 Million | 4.09 Million | 5.8 Million | 25.03 Million |
Operating Income | -1.61 Million | -3.64 Million | -4.76 Million | -6.49 Million |
Interest Expense | - | - | - | 23 Thousand |
Income Tax Expense | -10 Thousand | 187 Thousand | -220 Thousand | -159 Thousand |
Earnings before Tax | -1.61 Million | -3.64 Million | -7.25 Million | -6.54 Million |
Net Income | -1.6 Million | -3.83 Million | -7.03 Million | -6.38 Million |
Earnings Per Share Basic | -0.41 | -0.97 | -1.78 | -1.61 |
Earnings Per Share Diluted | -0.41 | -0.97 | -1.78 | -1.61 |
Weighted Average Shares Outstanding | 3.96 Million | 3.96 Million | 3.96 Million | 3.96 Million |
Weighted Average Shares Outstanding (Diluted) | 3.96 Million | 3.96 Million | 3.96 Million | 3.96 Million |
Gross Margin | - | - | - | 0.28 |
EBIT Margin | - | - | - | -0.23 |
Profit Margin | - | - | - | -0.41 |
EBITDA | 720 Thousand | -1.24 Million | -2.56 Million | -3.65 Million |
Earnings Before Tax Margin | - | - | - | -0.42 |
Breakdown | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - |
Operating Expenses | 1.25 Million | 520 Thousand | 934 Thousand | 929 Thousand | 1.37 Million | 5.85 Million |
Selling, General and Administrative Expenses | - | - | - | - | - | - |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 1.09 Million | 2.05 Million | 2.5 Million | 2.56 Million | 10.74 Million | 4.2 Million |
Cost and Expenses | 1.25 Million | 520 Thousand | 934 Thousand | 929 Thousand | 1.37 Million | 5.85 Million |
Operating Income | -158 Thousand | 1.53 Million | 1.57 Million | 1.63 Million | 9.37 Million | -1.61 Million |
Interest Expense | - | - | - | - | - | - |
Income Tax Expense | 1.09 Million | 2.8 Million | 629.58 Thousand | 467.91 Thousand | 548.41 Thousand | -10 Thousand |
Earnings before Tax | -158 Thousand | 1.53 Million | 1.57 Million | 1.63 Million | 9.37 Million | -1.61 Million |
Net Income | -158 Thousand | -1.26 Million | 1.57 Million | 1.63 Million | 9.37 Million | -1.6 Million |
Earnings Per Share Basic | -0.04 | -0.32 | 0.40 | 0.41 | 2.37 | - |
Earnings Per Share Diluted | -0.04 | -0.32 | 0.40 | 0.41 | 2.37 | - |
Weighted Average Shares Outstanding | 3.95 Million | 3.93 Million | 3.93 Million | 3.98 Million | 3.95 Million | 3.96 Million |
Weighted Average Shares Outstanding (Diluted) | 3.95 Million | 3.93 Million | 3.93 Million | 3.98 Million | 3.95 Million | 3.96 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | 320 Thousand | 1.67 Million | 2.16 Million | 2.22 Million | 9.96 Million | - |
Earnings Before Tax Margin | - | - | - | - | - | - |
JAL
MEDICAMEQ
OGN
VBX
8159
FEVR